Shares of Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) were down 3.9% during trading on Wednesday . The stock traded as low as $13.25 and last traded at $13.36, with a volume of 79,617 shares changing hands. The stock had previously closed at $13.90.

Several analysts have recently commented on PRTK shares. BTIG Research reiterated a “buy” rating and issued a $45.00 target price on shares of Paratek Pharmaceuticals in a report on Friday, June 17th. HC Wainwright reiterated a “buy” rating on shares of Paratek Pharmaceuticals in a report on Tuesday, August 16th. Robert W. Baird reiterated an “outperform” rating and issued a $40.00 target price (up previously from $30.00) on shares of Paratek Pharmaceuticals in a report on Friday, June 17th. Guggenheim reiterated a “buy” rating on shares of Paratek Pharmaceuticals in a report on Tuesday, August 16th. Finally, Cantor Fitzgerald reiterated a “buy” rating on shares of Paratek Pharmaceuticals in a report on Wednesday, June 29th. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $35.88.

The company’s market capitalization is $310.22 million. The stock has a 50 day moving average price of $13.28 and a 200-day moving average price of $14.24.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/paratek-pharmaceuticals-inc-prtk-stock-price-down-3-9.html

Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its earnings results on Thursday, August 4th. The specialty pharmaceutical company reported ($1.69) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.66) by $0.03.

In other Paratek Pharmaceuticals news, CEO Michael Bigham bought 20,000 shares of the company’s stock in a transaction dated Thursday, June 23rd. The shares were purchased at an average price of $13.45 per share, for a total transaction of $269,000.00. Following the acquisition, the chief executive officer now owns 100,000 shares in the company, valued at approximately $1,345,000. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Fund Iv L.P. Omega bought 461,538 shares of the company’s stock in a transaction dated Monday, June 27th. The shares were acquired at an average price of $13.00 per share, for a total transaction of $5,999,994.00. The disclosure for this purchase can be found here. Insiders own 2.00% of the company’s stock.

Several hedge funds have recently made changes to their positions in the stock. BVF Inc. IL acquired a new stake in shares of Paratek Pharmaceuticals during the second quarter worth approximately $7,998,000. Omega Fund Management LLC boosted its stake in shares of Paratek Pharmaceuticals by 21.6% in the second quarter. Omega Fund Management LLC now owns 2,600,410 shares of the specialty pharmaceutical company’s stock worth $36,172,000 after buying an additional 461,538 shares during the period. Numeric Investors LLC acquired a new stake in shares of Paratek Pharmaceuticals during the second quarter worth approximately $4,335,000. General American Investors Co. Inc. boosted its stake in shares of Paratek Pharmaceuticals by 72.2% in the second quarter. General American Investors Co. Inc. now owns 477,076 shares of the specialty pharmaceutical company’s stock worth $6,636,000 after buying an additional 200,000 shares during the period. Finally, Opaleye Management Inc. acquired a new stake in shares of Paratek Pharmaceuticals during the second quarter worth approximately $2,041,000. Hedge funds and other institutional investors own 77.18% of the company’s stock.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc (Paratek), formerly Transcept Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek’s antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI).

5 Day Chart for NASDAQ:PRTK

Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.